Search | Clinical Trials Finder

Conditions: Clostridium Difficile
Interventions: C. difficile vaccine with adjuvant, placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Overland Park, Kansas • Cary, North Carolina • Raleigh, North Carolina + 2 more

Conditions: Crohn's Disease
Interventions: Fecal Microbial transplant, Normal Saline, rifaximin+omeprazole+miralax; Biological · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 12 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dermatitis, Allergic Contact
Interventions: rHuPH20, Placebo; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Michigan City, Indiana

Conditions: Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)
Interventions: Molgramostim nebulizer solution, PARI eFlow nebulizer system; Drug · Device
Lead sponsor: Savara Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Denver, Colorado • Orlando, Florida • New Hyde Park, New York + 2 more

Conditions: Healthy Adult Participants
Interventions: ARN-75039 oral capsules, Placebo; Drug
Lead sponsor: Arisan Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: health coaching; Behavioral
Lead sponsor: Sara Seifert; Industry
Eligibility: 40 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Substance Abuse, Substance Dependence, Alcohol Abuse, Drug Use, Relapse
Interventions: Dual Processing, Relapse Prevention; Behavioral
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Falls Church, Virginia

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 53
States / cities: Concord, California • La Jolla, California • Los Angeles, California + 47 more

Conditions: Atopic Dermatitis
Interventions: Placebo, Upadacitinib, Topical corticosteroids (TCS); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Periodontal Disease
Interventions: ST266, Saline (0.9% NaCl); Biological · Drug
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more

Conditions: Hemophilia A With Inhibitors
Interventions: rFVIIIFc; Biological
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more

Conditions: Post-Traumatic Headache
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more

Conditions: Glioblastoma Multiforme, Adult
Interventions: Berubicin, Lomustine; Drug
Lead sponsor: CNS Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 32
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange, California + 28 more

Conditions: Cirrhosis, Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, Covert Hepatic Encephalopathy
Interventions: 25% IV albumin, Placebo; Biological · Other
Lead sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cesarean Section Complications
Interventions: Erector Spinae Plane (ESP) Block, bupivacaine liposome injectable suspension, bupivacaine; Procedure · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypercholesterolemia, Heterozygous Familial
Interventions: mipomersen sodium 200 mg, Placebo, mipomersen sodium 70 mg; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 20
States / cities: Mission Viejo, California • Aurora, Colorado • Cooper City, Florida + 17 more

Conditions: Chronic Blepharitis
Interventions: Terpinen-4-ol, Placebo; Drug · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 15 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Substance-Related Disorders
Interventions: Letters; Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 851 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Eye Disorders
Interventions: Atropine 1%; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metastatic Colorectal Cancer
Interventions: 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 23
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more

Conditions: Knee Osteoarthritis
Interventions: KneeBRIGHT System, Control Exercise; Device · Other
Lead sponsor: Barron Associates, Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Rotator Cuff Tear Arthropathy
Interventions: Ibuprofen, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 54
States / cities: Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more

Conditions: Substance Use Disorders, Opiate Dependence, Opiate Withdrawal Syndrome, Opioid-use Disorder, Alcohol Withdrawal, Alcohol Abuse, Alcohol Use Disorder, Cocaine Abuse, Cocaine Use Disorder, Cocaine Withdrawal, Benzodiazepine Abuse, Benzodiazepine Dependence, Substance Abuse, Heroin Overdoses, Heroin Withdrawal, Heroin Abuse
Interventions: Six Step Model of Self-Forgiveness, Treatment as Usual (TAU); Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: McKeesport, Pennsylvania

Search by objective public record fields.

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Fecal Microbial Transplant in Pediatric Crohn's Disease

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

Home-Based Health Management of COPD Patients

fMRI Study of a Dual Process Treatment Protocol With Substance Dependent Adults

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

HEAL STUDY (Hepatic Encephalopathy and Albumin Study)

ESP Block for Post Cesarean Analgesia

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Demodex Blepharitis Treatment Study

Behavioral Insights to Encourage Judicious Prescribing of Opioids

APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

Knee Biofeedback Rehabilitation Through Game Therapy

Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder Functional Outcomes

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

The Effect of Self-Forgiveness on Self-Stigma in Addiction.